NextCell files patent application for treatment of COVID-19 with ProTrans
NextCell Pharma AB ("NextCell" or the "Company”) announces that a patent application has been filed for the treatment of Sars-CoV-2 mediated severe pneumonia with ProTrans.
NextCell increases the IP protection for the drug candidate ProTrans for the treatment of autoimmune diseases and inflammatory conditions. The latest patent application has is entitled; "Allogeneic Composition for Treatment off Covid-19". By using the possibility of priority from a previous application, the COVID-19 application has a priori day of August 14, 2020, i.e. dated 1 year back in time.
NextCell has filed a total of four international patent applications for
1. the selection algorithm and treatment of diabetes,
3. the treatment of the CNS,
4. treatment of COVID-19.
"The application is based on the clinical trials carried out with COVID-19 patients in Sweden and Canada. The time for priority is important and should provide good protection for ProTrans ", says Mathias Svahn, CEO.
The company cooperates with AWA Sweden AB to continuously evaluate patentability and freedom-to-operate for the business and the drug candidate ProTrans.
Stay up to date with the latest development in NextCell Pharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
About NextCell Pharma AB
NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is to take ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from IVO.
FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, email@example.com.